Stocks · News reference

B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5

Aug 14, 2026, 6:18 PMBenzinga Newsdesk

B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Neutral and lowers the price target from $6 to $5.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 19, 2026, 10:12 AMBenzinga Newsdesk
BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11
BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating and announces Price Target of $11.
Read original at benzinga
CATX
BenzingaAug 11, 2026, 7:53 PMBenzinga Newsdesk
Perspective Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
Read original at benzinga
CATX
BenzingaAug 11, 2026, 1:14 PMBenzinga Newsdesk
Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $14
Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight and lowers the price target from $16 to $14.
Read original at benzinga
CATX